An Ebola vaccine is different from the experimental Ebola drug ZMapp, which two Americans received last month and is designed to treat an existing Ebola infection rather than prevent one.
“There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, said in a statement.
The ongoing Ebola outbreak in West Africa prompted the National Institutes of Health to expedite safety testing for several vaccines already in the works. Since March, the deadly virus has killed 1,552 people, according to the World Health Organization, which predicted last week that the virus could infect 20,000 people in the next six months.
The NIH is developing the vaccine with pharmaceutical giant GlaxoSmithKline. Although Fauci said the vaccine has “performed extremely well” in primate studies, it has not yet been tested in humans.
The phase 1 clinical trial set to begin this week at the NIH Clinical Center in Bethesda, Maryland, will involve 20 human subjects between the ages of 18 and 50, according to the NIH.
Researchers will use the study to determine whether the vaccine is safe and see whether it prompts an immune response necessary to protect against Ebola. No human subjects will be infected with Ebola.
A $4.7 million grant will also go toward Ebola vaccine trials in September at the University of Oxford in England, as well as centers in Gambia and Mali, according to GlaxoSmithKline. In all, 140 patients will be tested.
Though Ebola was discovered nearly 40 years ago, it was so rare that drug manufacturers weren’t interested in investing in finding a vaccine for it, said Dr. William Schaffner, chair of preventive medicine at Vanderbilt University in Nashville, Tennessee. Its rarity also made it impossible for scientists to conduct field studies.
Although Fauci said in July that it would take until late 2015 for a vaccine -- if successful -- to be administered to a limited number of health workers, GlaxoSmithKline said in a statement that the grant will also enable it to manufacture 10,000 doses of the vaccine while the trials are ongoing. If the vaccine trials are successful, it will be able to make stocks available immediately to the World Health Organization.
The NIH said it should have initial data from the trial in late 2014.
The trial for different vaccine is set to begin at the Walter Reed Army Institute of Research in Silver Spring, Maryland. This vaccine was a collaboration between the federal Department of Defenseand Iowa pharmaceutical company NewLink Genetics Corp.
Health officials recently predicted that some 20,000 people could be infected before the current Ebola outbreak in West Africa is brought under control.
On Friday, Senegal became the sixth country to report cases of the deadly virus.
- AFRICA | DR Congo: eastern Ebola outbreak defeated, ‘mission impossible’ now a ‘sign of hope’
- DR Congo: Agencies appeal for funding for refugee support and Ebola response
- Investing in health systems is the only way to stop the next Ebola outbreak
- Why the DRC Ebola outbreak was declared a global emergency and why it matters
- JAMAICA | EBOLA Response Plan Activated to Increase Awareness
Latest from Calvin G. Brown
- JAMAICA | Jamaica records 7 new COVID-19 deaths, 230 additional cases
- JAMAICA | PM Holness, Former PM Patterson pay tribute to DK Duncan
- GUYANA | Opposition stonewalled, Gov't warned, stay out of Venezuela's internal affairs
- JAMAICA | Cabinet Ministers Sworn in amidst PM's call for judgement and Integrity
- GUYANA | APNU+AFC Coalition concerned over Pompeo's visit to Guyana